ASX ANNOUNCEMENT 30 October 2026 Quarterly Activities Report: Advancement of Stabl-Im clinical development and trial preparations • Key Stabl-Im development milestones achieved, with key technical, procedural and operational activities progressing towards planned Phase 1 clinical evaluation •...